[NICE] National Institute for Clinical Excellence (NICE). 2004. Chronic obstructive pulmonary disease: National clinical guidelines for manage- ment of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(Suppl 1):i1–i232. Nisar M, Earis J, Pearson M, et al. 1992. Acute bronchodilator trials in chron- ic obstructive pulmonary disease. Am Rev Respir Dis, 146:555–9. O’Brien A, Russo-Magno P, Karki A., et al 2001. Effects of withdrawal of inhaled corticosteroids in men with severe irreversible airﬂow obstruc- tion. Am J Respir Crit Care Med, 164:365–71. O’Donnell D, Forkert L, Webb K. 2001. Evaluation of bronchodilator responses in patients with „irreversible“ emphysema. Eur Respir J, 18:914–20. O’Donnell DE, Flüge T, Gerken F, et al. 2004a. Effects of tiotropium on lung hyperinﬂation, dyspnoea and exercise tolerance in COPD. Eur Respir J, 23:832–40. O’Donnell DE, Voduc N, Fitzpatrick M, et al. 2004b. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J, 24:86–94. O’Donnell D, Aaron S, Bourbeau J, et al 2003. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J, 10(Suppl A):11A–65A. Paggiaro PL, Dahle R, Bakran I, et al. 1998. Multicentre randomised pla- cebo-controlled trial of inhaled ﬂuticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet, 351:773–80. Pauwels R. 2001. GOLD: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1256–76. Pauwels R. 2002. Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full the glass? Am J Respir Crit Care Med, 165:1579–80. Pizzichini E, Pizzichini M, Gibson P, et al 1998. Sputum eosinophilia predicts beneﬁt from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med, 158:1511–17. Quanier P, Tammeling GJ, Cotes JE, et al. 1993. Lung volumes and forced ventilatory flows. Report working party; standardisation of lung function tests European Community for steel and coal. Eur Respir J, 6(Suppl 6):5–40. Sadowska A, van Overveld F, Górecka D., et al 2005. The interrelation- ship between markers of inﬂammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med, 99:241–9. Tiotropium or salmeterol plus treatment with ICS for COPD Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerba- tion on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:1418–22. Sin DD, Lacy P, York E, et al. 2004. Effects of ﬂuticasone on systemic markers of inﬂammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 170:760–5. Suissa S. 2006. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 173:842–6. Szafranski W, Cukier A, Ramirez A, et al. 2003. Efﬁcacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J, 21:74–81. Tashkin DP, Cooper C. 2004. The role of long-acting bronchodilators in the management of stable COPD. Chest, 125:249–59. van der Valk P, Monninkhof E, van der Palen J, et al. 2002. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med, 166:1358–63. van Noord JA, Aumann J-L, Jansenns E, et al. 2005. Comparison of tioro- pium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214–22. Van Noord J, de Munck D, Bantje T, et al. 2000. Long-term treatment of COPD with salmeterol and the additive effect of ipratropium. Eur Respir J, 15:878–85. van Noord JA, Aumann JL, Janssens E, et al. 2006. Effects of tiotropium with and without formoterol on airﬂow obstruction and resting hyper- inﬂation in patients with COPD. Chest, 129:509–17. Weir D, Bale G, Bright P, et al. 1999. A double-blind, placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy, 29:125–9. Wouters EFM, Postma DS, Fokkens B, et al. 2005. Withdrawal of ﬂuticasone propionate from combined salmeterol/ﬂuticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax, 60:480–7. International Journal of COPD 2007:2(2) 167